1. Scrip

Biogen ‘Ready To Launch’ Aducanumab If It Gets The Chance

 
• By Jessica Merrill

The company has identified 600 sites of care to treat Alzheimer's patients with aducanumab in the US and is confident on its pricing strategy, management said.

Biogen facility
Biogen investors are focused on the fate of aducanumab • Source: Alamy

It’s still a big question whether Biogen, Inc.’s aducanumab will be approved by the US Food and Drug Administration in the coming weeks for the treatment of Alzheimer's disease, but if it is, the company assured investors it is prepared to launch.

"We are ready to launch aducanumab in the US," CEO Michel Vounatsos said during the company's first quarter sales and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.